Skip to content

Post COVID-19 Pulmonary Rehabilitation Program

Outpatient and Home Pulmonary Rehabilitation Program for Post COVID-19 Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04982042
Acronym
COVID19REHAB
Enrollment
40
Registered
2021-07-29
Start date
2021-03-01
Completion date
2022-07-30
Last updated
2021-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorder; Mixed With Depression (Mild), Covid19, COVID-19 Respiratory Infection, Lung Diseases, Muscle Weakness, Respiratory Insufficiency

Keywords

COVID-19, Pulmonary Rehabilitation, Pulmonary Function, Respiratory Physiotherapy, Respiratory Insufficiency

Brief summary

Coronavirus-2019 disease (COVID-19) is a highly infectious respiratory disease that causes respiratory, physical and psychological dysfunction in patients. With the increased understanding of the severity of COVID-19 and clinical evidence in accordance with the opinions of first-line clinical experts involved in the treatment of this epidemic, the investigators believe that the participation of patients with sequelae of COVID-19 in a Pulmonary Rehabilitation Program would be of utmost importance. According to recent scientific recommendations for patients with sequelae of COVID-19, respiratory rehabilitation would alleviate symptoms of dyspnea, anxiety and depression and, eventually, improve physical functions and quality of life. Therefore, it is essential to anticipate early rehabilitation after the acute phase of ARDS, in order to limit the severity of the effects of the ICU and promote rapid functional recovery. Physiotherapy will play a role in providing exercise, mobilization and rehabilitation interventions for survivors of critical illnesses associated with COVID-19, in order to enable a functional social return.

Detailed description

The investigatores propose a clinical, prospective and consecutive study composed of participants with pulmonary sequelae of COVID-19 and pulmonary diseases such as COPD, Asthma, Bronchitis, Emphysema, Bronchiectasis and pulmonary fibrosis. Initially, all patients will undergo a physical assessment, pulmonary function tests and nutritional assessment, in addition to applying the modified dyspnea scale of the MMRC (Modified Medical Research Council) and the 6-minute walk test (6MWT), according to the standards recommended by the American Thoracic Society (ATS). The proposed Outpatient and Home Pulmonary Rehabilitation Program is based on the Guidelines recommended by the Brazilian Society of Pulmonology (SBPT) and by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), with a minimum duration of 12 weeks, frequency of 3 weekly sessions, accompanied by health professionals in this field. Patients who seek care at municipal and state health services in the city of Anápolis, (Goiás) will be recruited. Patients with clinically stabilized COVID - 19 sequelae will be considered eligible, and who agree to participate in the study, signing the Informed Consent . The outpatient PRP consisted of a combination of aerobic and strengthening exercises, lasting 12 weeks, frequency 3 times a week. Each session will consist of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.

Interventions

OTHERPulmonary Rehabilitation

The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.

Sponsors

Centro Universitário de Anapolis
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Only the outcome assessors will be blinded to the data due to the fact that we have a group of patients undergoing the Outpatient Rehabilitation Program and another group of patients undergoing the Home Rehabilitation Program with follow-up by Tele-Rehabilitation

Intervention model description

To compare the effects of an Outpatient and Home Pulmonary Rehabilitation Program aimed at patients with pulmonary sequelae resulting from COVID-19 and with other chronic lung diseases on clinical symptoms, level of physical activity, functional status, quality of life, survival and in health maintenance costs by the government.

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with a diagnosis of pulmonary sequelae post COVID-19 * Patients clinically stabilized * Who agreed to participate in the clinical study, signing the informed consent form, will be considered eligible.

Exclusion criteria

* Hospitalized patients * Patients who present clinical instability * Patients who do not commit to adhering to the Pulmonary Rehabilitation Program

Design outcomes

Primary

MeasureTime frameDescription
Functional status after Pulmonary Rehabilitation Program (COVID-19REHAB)12 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on levels of functional status assessed with the Medical Research Council (MRC) Scale in patients with pulmonary sequelae resulting from COVID-19.
Exercise capacity after Pulmonary Rehabilitation Program (COVID-19REHAB)12 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on exercise capacity assessed with the six minutes Walk Test ( 6MWT) in patients with pulmonary sequelae resulting from COVID-19.

Secondary

MeasureTime frameDescription
Quality of Life after Pulmonary Rehabilitation Program (COVID-19REHAB)12 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on the Quality of Life levels measured by Medical Outcomes Study/SF-36 Questionnaire in patients with pulmonary sequelae resulting from COVID-19.
Forced Vital Capacity after Pulmonary Rehabilitation Program (COVID-19REHAB)12 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on the forced vital capacity (FVC) measured by spirometry in patients with pulmonary sequelae resulting from COVID-19.
Forced Expiratory Volume in first second after Pulmonary Rehabilitation Program (COVID-19REHAB)12 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on the forced expiratory volume in first second (FEV1) measured by spirometry in patients with pulmonary sequelae resulting from COVID-19.
Inspiratory muscle strength after Pulmonary Rehabilitation Program (COVID-19REHAB)12 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on the inspiratory muscles strength measured by vacuometry in patients with pulmonary sequelae resulting from COVID-19.
Peripheral muscle strength after Pulmonary Rehabilitation Program (COVID-19REHAB)12 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on the peripheral muscle strength measured by Hand Grip Dynamometer in patients with pulmonary sequelae resulting from COVID-19.
Levels of anxiety and depression after Pulmonary Rehabilitation Program (COVID-19REHAB)12 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on the Anxiety and depression levels measured by the Hospital Anxiety and Depression scale in patients with pulmonary sequelae resulting from COVID-19.
Health costs after COVID - 19.36 weeksEffects of an Ambulatory and Home Pulmonary Rehabilitation Program on healthcare costs verified through the financial expenses of patients with pulmonary sequelae resulting from COVID-19.

Countries

Brazil

Contacts

Primary ContactLuis LV Oliveira, PhD
oliveira.lvf@gmail.com0055 62 999052309
Backup ContactLuis VF Oliveira, PhD
luis.oliveira@unievangelica.edu.br0055 62 999052309

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026